Ascletis’s daily acne tablet set for China review after Phase III win
The Phase III trial, conducted by Chinese license partner Ascletis, produced strong results for denifanstat compared to potential rivals.
ASCO25: Genmab鈥檚 Rina-S en route to 鈥榖lockbuster potential鈥� amid further positive data
Roche extends SMA market lead with Evrysdi tablet approval in Europe
ASCO25: AbbVie flexes ADC Phase I data as NSCLC market opportunity beckons
EC approves Takeda ADC plus chemo for stage IIb Hodgkin’s lymphoma
ASCO25: J&J鈥檚 trispecific antibody shows 100% response in Phase I multiple myeloma study
色界吧
View More
Themes
View MorePharma鈥檚 AI prospects get nudged into the future with EU鈥檚 AI act聽
Experts predict growing pains as the life sciences sector moves to adapt to the EU AI Act.
More themes
Data Insights
View MoreCell & gene therapy: the leading companies in recombinant AAV gene therapy revealed
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Discover Data Insights powered by our proprietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
More Insights
Buyer's Guides
View More
Digital health and digital therapeutics (DTx) services and providers for the pharmaceutical industry
Digital Magazine
View MorePharma Technology Focus
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Next-generation targeting for evolving HCP engagement
Are regulators keeping pace with AI adoption in clinical trials?
Recursion axes drug programmes to streamline pipeline 聽
AstraZeneca enters $200m AI cancer pact with Tempus and Pathos